Form 4: Lyell Immunopharma Director Elizabeth Nabel Acquires Options

Director Elizabeth Nabel acquired options to purchase 130,000 shares of Lyell Immunopharma stock on June 14, 2024.

Summary

• Elizabeth Nabel, a director of Lyell Immunopharma, acquired options to purchase 130,000 shares of the company's common stock on June 14, 2024.
• The exercise price of the options is $2.36 per share.
• The options vest on the earlier of the next annual meeting of stockholders following June 14, 2024, or the first anniversary of that date, contingent upon continuous service as a director.
• A power of attorney was executed, granting Matthew Lang, Charles Newton, Hector Casab, Anitha Anne, and Allison Peth the authority to file Forms 3, 4, and 5 on behalf of Elizabeth Nabel.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing an option grant, which doesn't inherently indicate positive or negative sentiment about the company's performance.

Positives

• The acquisition of options by a director could be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the option grant suggests an expectation of continued service by the director.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies within the biotechnology and pharmaceutical industries. These transactions are closely monitored by investors for insights into management's confidence in the company's prospects.

Comparison to Industry Standards

• Option grants to directors are a common practice in publicly traded companies, particularly in the biotech industry, as a way to align their interests with those of shareholders.
• The vesting schedule and exercise price are typical for such grants, often tied to continued service and market prices at the time of the grant.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also regularly issue stock options to their directors and executives as part of their compensation packages.

Stakeholder Impact

• The option grant could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence by the director.

Key Dates